Literature DB >> 23335494

Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study.

Nelson Kinnersley1, Simon Day.   

Abstract

To quantify uncertainty in a formal manner, statisticians play a vital role in identifying a prior distribution for a Bayesian-designed clinical trial. However, when expert beliefs are to be used to form the prior, the literature is sparse on how feasible and how reliable it is to elicit beliefs from experts. For late-stage clinical trials, high importance is placed on reliability; however, feasibility may be equally important in early-stage trials. This article describes a case study to assess how feasible it is to conduct an elicitation session in a structured manner and to form a probability distribution that would be used in a hypothetical early-stage trial. The case study revealed that by using a structured approach to planning, training and conduct, it is feasible to elicit expert beliefs and form a probability distribution in a timely manner. We argue that by further increasing the published accounts of elicitation of expert beliefs in drug development, there will be increased confidence in the feasibility of conducting elicitation sessions. Furthermore, this will lead to wider dissemination of the pertinent issues on how to quantify uncertainty to both practicing statisticians and others involved with designing trials in a Bayesian manner.
Copyright © 2013 John Wiley & Sons, Ltd.

Mesh:

Year:  2013        PMID: 23335494     DOI: 10.1002/pst.1552

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  12 in total

Review 1.  Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessment.

Authors:  Bogdan Grigore; Jaime Peters; Christopher Hyde; Ken Stein
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

Review 2.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

3.  A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials.

Authors:  Kevin Kunzmann; Michael J Grayling; Kim May Lee; David S Robertson; Kaspar Rufibach; James M S Wason
Journal:  Am Stat       Date:  2021-04-22       Impact factor: 8.710

4.  Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations.

Authors:  Cynthia P Iglesias; Alexander Thompson; Wolf H Rogowski; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

5.  Bayesian methods for the design and interpretation of clinical trials in very rare diseases.

Authors:  Lisa V Hampson; John Whitehead; Despina Eleftheriou; Paul Brogan
Journal:  Stat Med       Date:  2014-06-23       Impact factor: 2.373

Review 6.  Decision-theoretic designs for small trials and pilot studies: A review.

Authors:  Siew Wan Hee; Thomas Hamborg; Simon Day; Jason Madan; Frank Miller; Martin Posch; Sarah Zohar; Nigel Stallard
Journal:  Stat Methods Med Res       Date:  2015-06-05       Impact factor: 3.021

7.  Evidence, eminence and extrapolation.

Authors:  Gerald Hlavin; Franz Koenig; Christoph Male; Martin Posch; Peter Bauer
Journal:  Stat Med       Date:  2016-01-11       Impact factor: 2.373

8.  Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.

Authors:  Michael Pearce; Siew Wan Hee; Jason Madan; Martin Posch; Simon Day; Frank Miller; Sarah Zohar; Nigel Stallard
Journal:  BMC Med Res Methodol       Date:  2018-02-08       Impact factor: 4.615

9.  Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution.

Authors:  Siew Wan Hee; Nicholas Parsons; Nigel Stallard
Journal:  Biom J       Date:  2017-07-26       Impact factor: 2.207

10.  Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.

Authors:  Cathie Spino; Jordan S Jahnke; David T Selewski; Susan Massengill; Jonathan Troost; Debbie S Gipson
Journal:  Front Pediatr       Date:  2016-03-23       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.